progress Lucinda, you It's to all. Thank on a pipeline for you you, XXXX. for joining third pleasure like X, Slide good If give move Thank to and quarter morning operating key to the the my update quick activities. us. our I'd review to we
our of which progressing with our the by study of very the the the for reiterating well. in multicenter XXXX. is the study track. we of FELIX data portion Phase delivered of program, our full in obe-cel, And that all, available are Enrollment lead be will next first guidance And is on end data year primary endpoint consequently, the middle pivotal II
X-month data position Ib the the we far ALLCAR to cell of are that observed from portion complete relapsed/refractory in over patients in pleased in XX initial be from safety running are the study response the Furthermore, the reported with data, Felix multicenter Phase so rate study, where we this the to observations acute of update consistent you and adult academic lymphoblastic leukemia. the
the later and Clearly, we at ASH. this Ib to very this year Phase from encouraging, early data this is cohort present plan
additional data next-generation CARPALL on the non-Hodgkin's clinical of extension first addition, data in B-cell in In obe-cel from is well, early indolent the the evaluating as ASH study, AUTO [ALM]. update indications you extension to also which ALLCARXX expect as at pediatric our X/XX, from we study lymphoma product,
update of an peripheral half first flow, lymphoma in AUTOX trial obe-cel the news T-cell to we plan of on I our addition in Phase also In to provide XXXX. the
from general move corporate walk you Slide quarter. updates through X, like a If we we'd third the to to
as roles. industry, the in business brings period, This experience commercial Firstly, look Nonexecutive we is were and to oncology the the and as leadership executive, announce towards delighted of H. of Autolus be commercial John of a a and during invaluable appointment to this obe-cel. number a biopharmaceutical we John operational launch Johnson commercial of clearly held having leader wealth Chairman. experience recognized will
to also planning This will and further anticipate granted Autolus expand integrated facility a a facility commercial announce obe-cel, that company. September, is our be capacity a will square leased We're another to foot XX,XXX demand pleased GMP step manufacturing if to that beyond Stevenage, approval batches will the approximately have needed. for global in as We very built for in indications year, was U.K. becoming that will meet this also company's initial of for it and X,XXX to new for fully Autolus scope journey build the a important to our it be on
of other This to President Resources. follows and Chief Chris updates, terms Swan, a future. our Alex and of Alder, we Corporate Williams Autolus the Matthias to to wish promoted grateful Matthias him Officer, from of and departure for to extremely Human President for In Development; Vice Senior best of his we're Vice the Business service Senior all
Alex Chris senior leadership and welcome team. are to the We to delighted
us QX new very of of the we Brugger, who Wolfram the as Officer as has well to As new company; Development appointment Clinical the Edgar as pleased the now the as part of Chief who as announce Braendle, joined as earnings also events, announced were post-period Head Development. joined Dr. us of
Moderna developed up the license binders is to further have This X and incorporating therapeutics company. for where Finally, we license recognition and base we to Moderna, within announced technology mRNA exclusive the targets. immuno-oncology with develop granted that an an agreement commercialize tangible proprietary Autolus' option we of
to is by the we'd move on provide first regards on the What Autolus. Slide is do to slide, With to a that, let's track commercially obe-cel, with X. to brief launched overview be like next product to which
on remember, for relapsed/refractory with adult our the is focus FELIX patients ALL. delivering the company study you As in
both post-blinatumomab and inotuzumab, study have just relapsed yet or and received are not who may as well in the have inotuzumab are enrolling that but With setting patients patients as blinatumomab. the progressing not
the and ALLCARXX at released expect June provide EHA mentioned also obe-cel to in beyond the year. we study, data further As of to of the already all Extension we're in earlier, context updates we exploring of this activity QX XXXX in the
addition DLBCL follicular and with lymphoma and data In on updates the to patients we cell patients, CLL. will include on mantle also
also are addition, In the novel with a that adding patients builds a is AUTOX/XX, which CDXX by newer product receptor. antigen obe-cel now pediatric backbone upon we treating
share initial As expect mentioned on product to XXXX. clinical data of previously, also we the this some also in QX
Next slide, please, Slide X.
the Focusing current was specifically what in limitations Obe-cel adult believe it's are why leukemia, worth designed successful key of of underlying that's placed a it's lymphoblastic address of this therapy to we remembering biology on for acute to CAR uniquely adult therapy features ALL, the indication. cell indication. and specifically tackle this the
better at disease off core less like the that disease, to proliferating another and will and lower cell persistence. patients of releases with nature. would poor challenge because And in whereby the target, also more it's less of and hence, inflammation that same being the engraftment quickly, with and cell fast present and Then binder [indiscernible] experience exhaustion see of interaction obe-cel, condition. expect a is we often rate cells time, the toxicity. quicker its the fast the this means interacts levels One with that target The more very efficient of in challenges is
Slide X. to move Please
new unmet Whilst you, combination adult me approximately in and to of last XX% about achieve worldwide remains medical in reside setting. ALL enables EU. the the cases Approximately ALL these CRS, X,XXX to cases remind U.S. a diagnosed adult high XX% remission. Let chemotherapy X,XXX line need very yearly this only XX% of patients still with for will achieve longer-term
real elotuzumab of blinatumomab year. orphan the you drug for relapsed, obe-cel and We profile this setting. approved ALL; designation than opportunity process less been believe, designation a for this EMA; countries, MHRA. granted ILAC median some launched. in in product with being candidate a a in overall designation by patients a products the for however, to The Tecartus Once remains have include survival has Prime by And remind there indication and by and of is all, obe-cel's FDA
Moving on XX. Slide to
So measured on new survival. at by ALLCAR let's were data the to for recently update event-free a data notably on EHA take an to presented durability just of Key study, moment the response as date. presented recap
already you of in CAR-T As obe-cel product levels has would high the communicated, and this indication, of response. we've as expect cell initial
treatment, go with emerging the is evidence it that maintained post proportion obe-cel into gives curve, the However, get This time. of what patients a these remission. us has the over potential as good Kaplan-Meier is stabilizing event-free a long-term now in seeing survival patients that confidence we're the to out level of
of this response other in increase long-term of degree over So since the basic of with for provides with do seen of that turning in the its plateau setting. maintained reported Furthermore, XX. response CAR-T has a To have that to such persistence but it our time. obe-cel only been is the design premise tenfold long this Slide of the cells a about time disease exceptional is first seeing we the the a product. knowledge, validation programs, maximum level we're been in correlated cells see Not number that CAR-T is
it's seems this a prerequisite and translate molecular remission response is be long-term to belief And indication, into our data persistence this. actually able emerging that to a in a to the support
adverse previously, right-hand And slide, as On syndrome. we also see of the profile. you'll cytokine seen event release reported the side haven't the high-grade
these limited tocilizumab care was intervention patients. and no only and achieved as prospective supportive without steroids this of in such use with Furthermore, and use vasopressor
safety setting. good hypothesis safety for upon potentially obe-cel the conclusion, So which data should efficacy profile, product again, having this easily render a as very unique product, would obe-cel the more and the encouraging clinical based manageable be a design very the has is clinic. in In anticipated in with profile the
XX. of the context approvals it put that the for used the and the in space, published were moving I'd inotuzumab. products blinatumomab existing To So to Slide the to this into compare for foundation the first like datasets to other of data on standard the care and data with
levels far, data Overall, both thus offering potential particularly in as more high see, of of a these with against very the available for sustained obe-cel for respect can of programs, activity response. up you well stacks
Slide to XX. Turning
with study. data in neurotoxicity excellent patients obe-cel's the the label. would it and and any relapsed/refractory response approval on event-free point observed approved ALL. efficacy like a with XX% supporting CUSTOMERS, you in persistence this rate XX% The grade side, compare the ALLCAR shows to recently patients complete high-grade And of was neurotoxicity to I in experiencing the survival Tecartus adult
encouraging safety need very efficacy very believe unique differentiated In based and is with we on safety this profile. of setting. clinical obe-cel for data we ALLCARXX have conclusion, nicely in high durability this overall medical we and feel potentially response population a taken profile product patient And having in a context, both
Slide please. XX,
ALL FELIX. inotuzumab, response and complete blina- X endpoints is blinatumomab as has regards to on to receiving adult of Moving obe-cel This the study primary as as event-free XXX-patient patients subpopulations, responses well and as endpoint or registration molecular is in experience to of post-exposed study a and well previously the It patients. survival The study, relapsed/refractory rate secondary relapsed/refractory with inotuzumab. the duration response. include patients
performance Amgen XX% of size as third patients, compared let but I'd and year-by-year reported in quarter on Blincyto, the the the highlight growth yesterday sorry, please. sales upon on basis quarter standard -- turn to I current third to So last terms blinatumomab. known as an the current in third year. earlier a of the to market of in the Slide care, sales the slide otherwise growth in us XX% quarter XX, of market opportunity ALL just is in touched what like size
commercial XXXX, XX look growth publicly information see, region XX%. If -- sales the in very typically further extrapolation million in of and a in to translates were XXXX around can sales the and simple patients million, the there about XXXX. at cycles you adult and of with available average this on patients, patients X $XXX receive globally approximately receiving if use and and a As this first this currently provides we sorry, pediatric of X,XXX $XXX that of apply by XXXX proportion half product, and on we evidence in using product
increase for to beyond Amgen Hospital the been centers. the academic has segment the of stated in expansion Community one U.S. underlying sales has key the drivers that transplant
properties nonacademic the experience also those to launch moving of establish developments is well obe-cel. also of ALL [Byanzi] a product CAR-T centers, in we for bode to in of Both DLBCL expect the Blincyto While with these centers. in
a Slide XX% pretreated have study, level well please. the sustained with remissions cell is summarizes and high of highly XX tolerated XX months. of transplant with situation without being and ALLCARXX with subsequent disease durability observed CR that for encouraging are efs high patient in patients achieved XX, used pool despite burden. a Obe-cel at heavily in of ALL. stem the current Slide XX we a From subset obe-cel
no Overall, observed the the sizable a unmet very or excited any XX% in CRS. grade for with opportunity market X clear grade these we're We swiftly. patients higher obe-cel about experiencing ICANS, need. And resolved medical in
were indications. At different a moving data the move tract shared Please this taking no in achieved X EHA dosed ALLCAR that all metabolic small with consistent to was safety patients profile Now, from population, In to June, response. a in the high-grade CRS. patients phase. other that the of ALL extension on and And in on we experiencing Slide this XX. complete observed [indiscernible] with
none the any patients Furthermore, experienced of of neurotoxicity. form
COVID and patients, metabolic died of related One the died of AES. unfortunately, The however, COVID in a patient, contracted remission. complete as consequence
and that remission. other skin, was be There a also was in developed event No surgically, patients all which progression. progressed one lesion single further patient were a the patients but who considered in could obviously, removed other
XX. Slide to on Moving
also of in patients mechanism evaluated malignancies. are patients localized the brain. collaboration well in as and Non-Hodgkin's at action the we're our of lymphoma ALLCARXX is B-cell and profile, its similar as DLBCL aggressive also We're being extension academic study. lymphoma other partners in evaluating the use exclusively CNS that CLL obe-cel's to as part Given in primary study, in use the UCL lymphoma in with the conducting CAROUSEL
of In us taken very programs overview pediatric the with in an will positive as malignancies. CDXX These together mentioned, already the give spectrum across extension addition, we're conducting a CARPALL activity the study patients. obe-cel of of of AUTOX/XX good
it toolkit relates and Slide our AACR of which developed suite that a at of some you forward Moving as generation year. Autolus, next reminder exciting in programs, solid tumor the programs. programs on. particularly XX, We're in last of the On first through move to these have the we brief clinic recall we technology looking and XXXX showcased will XXXX, to into into including broad
recently discovery modalities. in highlights signed the we binder work highly Moderna, skilled other potential and team which the our have to worth we It's also the of deal reiterating in-house here Autolus with applicability
Finally, on dates. alongside that programs Slide tabulated start the I have next-generation XX, we these you expected Phase can see
pediatric You clinical the ALL AUTOX/XX trial will note, as discussed, of started QX XXXX. we in
expect tumors also the into the QX will AUTOX the of solid half in move the next-generation in study clinic NG And to the XXXX. to enrolling also We in half XXXX. first finally, positive likely first AUTOX is in XXXX. move start multiple into AUTOX, GDX our of product clinic myeloma
the XX to call Slide I'd that, you. Thank With like to just turn over to Andrew. and turn over
